CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, has announced it will report second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following the announcement. Investors can access the live webcast from CytomX's website and register for the conference call. Participants are advised to register at least 10 minutes before joining. An archived replay of the webcast will be available on the company's website for those unable to attend the live event.
CytomX Therapeutics (Nasdaq: CTMX), un leader nelle terapie biologiche mascherate e attivate condizionatamente, ha annunciato che riporterà i risultati finanziari del secondo trimestre 2024 giovedì 8 agosto 2024, dopo la chiusura dei mercati statunitensi. L'azienda ospiterà una chiamata conferenza e una trasmissione webcast alle 17:00 ET / 14:00 PT subito dopo l'annuncio. Gli investitori possono accedere alla trasmissione in diretta dal sito web di CytomX e registrarsi per la chiamata conferenza. Si consiglia ai partecipanti di registrarsi almeno 10 minuti prima di unirsi. Una registrazione archiviata della trasmissione sarà disponibile sul sito dell'azienda per coloro che non possono partecipare all'evento dal vivo.
CytomX Therapeutics (Nasdaq: CTMX), un líder en terapias biológicas enmascaradas y activadas condicionalmente, ha anunciado que reportará los resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, después del cierre de los mercados en Estados Unidos. La compañía llevará a cabo una videoconferencia y webcast a las 5:00 p.m. ET / 2:00 p.m. PT tras el anuncio. Los inversores pueden acceder a la transmisión en vivo desde el sitio web de CytomX y registrarse para la conferencia. Se aconseja a los participantes registrarse al menos 10 minutos antes de unirse. Una reproducción archivada del webcast estará disponible en el sitio web de la empresa para aquellos que no puedan asistir al evento en vivo.
CytomX Therapeutics (Nasdaq: CTMX)는 조건적으로 활성화된 마스크 생물학 치료제의 선두주자로서 2024년 2분기 재무 결과를 2024년 8월 8일 목요일, 미국 시장 종료 후 발표한다고 발표했습니다. 회사는 발표 후 동부 표준시 오후 5시 / 태평양 시간 오후 2시에 전화회의 및 웹캐스트를 진행할 예정입니다. 투자자들은 CytomX 웹사이트에서 생중계에 접근할 수 있으며 전화회의에 등록할 수 있습니다. 참가자는 최소 10분 전에 등록할 것을 권장합니다. 생중계에 참석할 수 없는 분들을 위해 회사 웹사이트에 아카이브된 재생본이 제공될 예정입니다.
CytomX Therapeutics (Nasdaq: CTMX), un leader dans les thérapies biologiques masquées et activées de manière conditionnelle, a annoncé qu'elle publiera les résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024, après la fermeture des marchés américains. La société organisera une conférence téléphonique et un webinaire à 17h00 ET / 14h00 PT suite à l'annonce. Les investisseurs peuvent accéder au webinaire en direct depuis le site de CytomX et s'inscrire pour la conférence téléphonique. Il est conseillé aux participants de s'inscrire au moins 10 minutes avant de rejoindre. Un enregistrement archivé du webinaire sera disponible sur le site de la société pour ceux qui ne peuvent pas assister à l'événement en direct.
CytomX Therapeutics (Nasdaq: CTMX), ein führendes Unternehmen im Bereich maskierter, bedingt aktivierter biologischer Therapeutika, hat bekannt gegeben, dass es am Donnerstag, den 8. August 2024, die finanziellen Ergebnisse für das zweite Quartal 2024 nach dem Abschluss der US-Märkte bekannt geben wird. Das Unternehmen wird um 17:00 Uhr ET / 14:00 Uhr PT nach der Ankündigung eine Telefonkonferenz und ein Webcast abhalten. Investoren können den Live-Webcast über die Website von CytomX abrufen und sich für die Telefonkonferenz registrieren. Den Teilnehmern wird geraten, sich mindestens 10 Minuten vor dem Eintritt zu registrieren. Eine archivierte Wiederholung des Webcasts wird für diejenigen verfügbar sein, die nicht an der Live-Veranstaltung teilnehmen können, auf der Unternehmenswebsite.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When will CytomX Therapeutics (CTMX) report its Q2 2024 financial results?
What time is CytomX Therapeutics' (CTMX) Q2 2024 earnings call scheduled for?
How can investors access CytomX Therapeutics' (CTMX) Q2 2024 earnings webcast?
Will there be a replay available for CytomX Therapeutics' (CTMX) Q2 2024 earnings call?
